Omideon
Private Company
Funding information not available
Overview
Omideon is a private, preclinical-stage biotech developing a new therapeutic modality centered on carbohydrate binding molecules (CBMs) to target cancer-specific glycans. Spun out from Pneumagen Limited, the company leverages a platform to engineer multivalent CBMs with high affinity for Tumor-Associated Carbohydrate Antigens (TACAs), aiming to disrupt multiple cancer-promoting pathways. Its lead asset, OMI-DG1, has shown in vivo proof-of-concept in ovarian cancer, and the company is seeking financing to advance it and expand into colorectal cancer. Omideon represents a novel approach in oncology by directly targeting the tumor glycome, an underexplored area with significant therapeutic potential.
Technology Platform
Platform for engineering multivalent carbohydrate binding molecules (CBMs) to target Tumor-Associated Carbohydrate Antigens (TACAs) on cancer cells.
Opportunities
Risk Factors
Competitive Landscape
The field of glycan-targeting cancer therapeutics is emerging but not yet crowded. Competition may come from other modalities like glycan-specific antibodies or small molecules. Omideon's engineered CBM approach is distinct and aims for multi-valent, high-affinity targeting.